Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biologics in refractory vasculitis
ISRCTN16502655Phase 2Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2 trial of rituximab, tocilizumab and infliximab, sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Jun 2021; status: terminated.
02
Drugs
rituximabtocilizumabinfliximab
Beyond the preview
Go deeper on ISRCTN16502655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16502655.